SynthesisRadiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology2012
Individual patient data meta-analysis shows no association between the SNP rs1800469 in TGFB and late radiotherapy toxicity.
Synthesis in Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 4 syntheses or guidelines pooled it, 70 citations in OpenAlex.
- Irinotecan-induced toxicity pharmacogenetics: an umbrella review of systematic reviews and meta-analyses.The pharmacogenomics journal · 2017Pooled it
- Individual patient data meta-analysis shows a significant association between the ATM rs1801516 SNP and toxicity after radiotherapy in 5456 breast and prostate cancer patients.Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2016Pooled it
- Radiogenomics: using genetics to identify cancer patients at risk for development of adverse effects following radiotherapy.Cancer discovery · 2014Pooled it
- No association between TGFB1 polymorphisms and late radiotherapy toxicity: a meta-analysis.PloS one · 2013Pooled it
- Association between SNPs in defined functional pathways and risk of early or late toxicity as well as individual radiosensitivity.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2015Trial
- A three-stage genome-wide association study identifies a susceptibility locus for late radiotherapy toxicity at 2q24.1.Nature genetics · 2014Trial
- Predictive Factors for Acute and Late Genitourinary and Gastrointestinal Toxicity Following Modern Radiotherapy for Prostate Cancer: A Narrative Review of Clinical, Dosimetric, Immunological, and Genetic Determinants.Life (Basel, Switzerland) · 2026Review
- Radiation pneumonitis in relation to pulmonary function, dosimetric factors, TGFβ1 expression, and quality of life in breast cancer patients receiving post-operative radiotherapy: a prospective 6-month follow-up study.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2023Article
- Investigation of the physiological response of radiation-induced cystitis patients using hyperbaric oxygen.Clinical and translational radiation oncology · 2023Article
- Association of polymorphisms in TGFB1, XRCC1, XRCC3 genes and CD8 T-lymphocyte apoptosis with adverse effect of radiotherapy for prostate cancer.Scientific reports · 2022Article
- Low dose ionizing radiation effects on the immune system.Environment international · 2021Review
- Genomics models in radiotherapy: From mechanistic to machine learning.Medical physics · 2020Review
- The Possibility of Using Genotoxicity, Oxidative Stress and Inflammation Blood Biomarkers to Predict the Occurrence of Late Cutaneous Side Effects after Radiotherapy.Antioxidants (Basel, Switzerland) · 2020Article
- Radiation biology and oncology in the genomic era.The British journal of radiology · 2018Review
- Role of Germline Genetics in Identifying Survivors at Risk for Adverse Effects of Cancer Treatment.American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting · 2018Review
- Radiation-Induced Fibrosis: Mechanisms and Opportunities to Mitigate. Report of an NCI Workshop, September 19, 2016.Radiation research · 2017Article
- Radiogenomics: A systems biology approach to understanding genetic risk factors for radiotherapy toxicity?Cancer letters · 2016Review
- Big Data Analytics for Prostate Radiotherapy.Frontiers in oncology · 2016Review
- A Preliminary Study on Racial Differences in HMOX1, NFE2L2, and TGFβ1 Gene Polymorphisms and Radiation-Induced Late Normal Tissue Toxicity.International journal of radiation oncology, biology, physics · 2015Article
- Exploiting biological and physical determinants of radiotherapy toxicity to individualize treatment.The British journal of radiology · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors at 1 institution in 1 country.
Funding
Abstract
background and purposeReported associations between risk of radiation-induced normal tissue injury and single nucleotide polymorphisms (SNPs) in TGFB1, encoding the pro-fibrotic cytokine transforming growth factor-beta 1 (TGF-β1), remain controversial. To overcome publication bias, the international Radiogenomics Consortium collected and analysed individual patient level data from both published and unpublished studies. MATERIALS AND
methodsTGFB1 SNP rs1800469 c.-1347T>C (previously known as C-509T) genotype, treatment-related data, and clinically-assessed fibrosis (measured at least 2years after therapy) were available in 2782 participants from 11 cohorts. All received adjuvant breast radiotherapy. Associations between late fibrosis or overall toxicity, reported by STAT (Standardised Total Average Toxicity) score, and rs1800469 genotype were assessed.
resultsNo statistically significant associations between either fibrosis or overall toxicity and rs1800469 genotype were observed with univariate or multivariate regression analysis. The multivariate odds ratio (OR), obtained from meta-analysis, for an increase in late fibrosis grade with each additional rare allele of rs1800469 was 0.98 (95% Confidence Interval (CI) 0.85-1.11). This CI is sufficiently narrow to rule out any clinically relevant effect on toxicity risk in carriers vs. non-carriers with a high probability.
conclusionThis meta-analysis has not confirmed previous reports of association between fibrosis or overall toxicity and rs1800469 genotype in breast cancer patients. It has demonstrated successful collaboration within the Radiogenomics Consortium.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.